 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| BI 764198 / Boehringer Ingelheim
Trial completion: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - Jan 10, 2025
P2, N=67, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed
- || BI 764198 / Boehringer Ingelheim
Enrollment closed: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - Oct 16, 2024
P2, N=60, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- BI 764198 / Boehringer Ingelheim
Targeting Podocyte Calcium Influx with TRPC6 Inhibitor BI 764198: Implications for Glomerular Filtration Barrier Protection (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3196;
Recruiting --> Active, not recruiting The findings provide in vitro validation of the therapeutic potential of the selective TRPC6 inhibitor BI 764198, shedding light on its protective mechanism of action.
- || BI 764198 / Boehringer Ingelheim
P2 data, Journal: TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design. (Pubmed Central) - Dec 18, 2023
The findings provide in vitro validation of the therapeutic potential of the selective TRPC6 inhibitor BI 764198, shedding light on its protective mechanism of action. No abstract available
- || BI 764198 / Boehringer Ingelheim
Trial completion, Enrollment change: A Study in Healthy Men to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Nov 13, 2023
P1, N=24, Completed, Sponsor: Boehringer Ingelheim
No abstract available Recruiting --> Completed | N=16 --> 24
- || BI 764198 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Aug 2, 2023
P1, N=16, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=16 --> 24 Active, not recruiting --> Recruiting
- | BI 764198 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Healthy Men to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Jul 28, 2023
P1, N=8, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Recruiting Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jul 2023 --> Nov 2023
- || BI 764198 / Boehringer Ingelheim
Enrollment closed, Enrollment change: A Study in Healthy Men to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Jun 23, 2023
P1, N=8, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jul 2023 --> Nov 2023 Recruiting --> Active, not recruiting | N=16 --> 8
- || BI 764198 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - May 17, 2023
P1, N=16, Recruiting, Sponsor: Boehringer Ingelheim
- || BI 764198 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - Mar 21, 2023
P2, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=16 --> 8 Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- BI 764198 / Boehringer Ingelheim
Study Design of a Phase 2a trial of BI 764198, a Transient Receptor Potential Channel 6 (TRPC6) Inhibitor, in Focal Segmental Glomerulosclerosis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 15, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_4569;
P2
In the US, selected study centres will partake in the NEPTUNE (Nephrotic Syndrome Study Network) programme. As such, this study, as a NEPTUNE-Match trial, will help generate data towards a precision medicine approach for the care of patients with FSGS and help inform target patient populations for future trials of BI 764198 in FSGS and other proteinuric diseases.
- BI 764198 / Boehringer Ingelheim
Study Design of a Phase 2a trial of BI 764198, a Transient Receptor Potential Channel 6 (TRPC6) Inhibitor, in Focal Segmental Glomerulosclerosis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 15, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3917;
P2
In the US, selected study centres will partake in the NEPTUNE (Nephrotic Syndrome Study Network) programme. As such, this study, as a NEPTUNE-Match trial, will help generate data towards a precision medicine approach for the care of patients with FSGS and help inform target patient populations for future trials of BI 764198 in FSGS and other proteinuric diseases.
- BI 764198 / Boehringer Ingelheim
Study Design of a Phase 2a trial of BI 764198, a Transient Receptor Potential Channel 6 (TRPC6) Inhibitor, in Focal Segmental Glomerulosclerosis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_862;
P2
In the US, selected study centres will partake in the NEPTUNE (Nephrotic Syndrome Study Network) programme. As such, this study, as a NEPTUNE-Match trial, will help generate data towards a precision medicine approach for the care of patients with FSGS and help inform target patient populations for future trials of BI 764198 in FSGS and other proteinuric diseases.
- || BI 764198 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - Jul 26, 2022
P2, N=60, Recruiting, Sponsor: Boehringer Ingelheim
As such, this study, as a NEPTUNE-Match trial, will help generate data towards a precision medicine approach for the care of patients with FSGS and help inform target patient populations for future trials of BI 764198 in FSGS and other proteinuric diseases. Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
- ||| BI 764198 / Boehringer Ingelheim
Enrollment open: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - Mar 21, 2022
P2, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Jul 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- |||| BI 764198 / Boehringer Ingelheim
New P2 trial: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - Jan 27, 2022
P2, N=60, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 764198 / Boehringer Ingelheim
Trial completion: A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated (clinicaltrials.gov) - Oct 31, 2021
P1, N=44, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || BI 764198 / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated (clinicaltrials.gov) - Oct 4, 2021
P1, N=44, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| BI 764198 / Boehringer Ingelheim
Trial termination: ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19 (clinicaltrials.gov) - Apr 22, 2021
P2, N=133, Terminated, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Terminated; Company decision
- || BI 764198 / Boehringer Ingelheim
Trial completion: A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood (clinicaltrials.gov) - Mar 21, 2021
P1, N=28, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Terminated; Company decision Active, not recruiting --> Completed
- || BI 764198 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated (clinicaltrials.gov) - Feb 14, 2021
P1, N=44, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || BI 764198 / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood (clinicaltrials.gov) - Feb 8, 2021
P1, N=28, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || BI 764198 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood (clinicaltrials.gov) - Jan 28, 2021
P1, N=28, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| BI 764198 / Boehringer Ingelheim
Enrollment change: ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19 (clinicaltrials.gov) - Jan 26, 2021
P2, N=130, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=90 --> 130
- || BI 764198 / Boehringer Ingelheim
Trial completion: A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Dec 19, 2020
P1, N=28, Completed, Sponsor: Boehringer Ingelheim
N=90 --> 130 Active, not recruiting --> Completed
- || BI 764198 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated (clinicaltrials.gov) - Dec 13, 2020
P1, N=44, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 764198 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood (clinicaltrials.gov) - Dec 7, 2020
P1, N=28, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| BI 764198 / Boehringer Ingelheim
Enrollment open: ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19 (clinicaltrials.gov) - Nov 19, 2020
P2, N=90, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || BI 764198 / Boehringer Ingelheim
Enrollment closed: A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Nov 19, 2020
P1, N=28, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| BI 764198 / Boehringer Ingelheim
Trial completion: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198 (clinicaltrials.gov) - Nov 4, 2020
P1, N=52, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Completed
- | BI 764198 / Boehringer Ingelheim
#Internacional | @Boehringer ha anunciado el inicio de un ensayo clínico de fase II de BI 764198 https://t.co/MAttiLXn0h (Twitter) - Oct 29, 2020
- |||| BI 764198 / Boehringer Ingelheim
New P2 trial: ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19 (clinicaltrials.gov) - Oct 26, 2020
P2, N=90, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 764198 / Boehringer Ingelheim
Enrollment open: A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Aug 7, 2020
P1, N=32, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Suspended --> Recruiting
- ||| BI 764198 / Boehringer Ingelheim
Enrollment open: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198 (clinicaltrials.gov) - Jul 16, 2020
P1, N=52, Recruiting, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting Suspended --> Recruiting
- BI 764198 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Jul 7, 2020
P1, N=32, Suspended, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: Jun 2020 --> Oct 2020
- BI 764198 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198 (clinicaltrials.gov) - May 7, 2020
P1, N=52, Suspended, Sponsor: Boehringer Ingelheim
Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: Jun 2020 --> Oct 2020 Trial completion date: May 2020 --> Aug 2020 | Trial primary completion date: May 2020 --> Aug 2020
- ||| BI 764198 / Boehringer Ingelheim
Trial suspension: A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Apr 6, 2020
P1, N=32, Suspended, Sponsor: Boehringer Ingelheim
Trial completion date: May 2020 --> Aug 2020 | Trial primary completion date: May 2020 --> Aug 2020 Recruiting --> Suspended
- |||| BI 764198 / Boehringer Ingelheim
Trial suspension: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198 (clinicaltrials.gov) - Apr 6, 2020
P1, N=52, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Recruiting --> Suspended
- || BI 764198 / Boehringer Ingelheim
Enrollment open: A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Dec 22, 2019
P1, N=32, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Not yet recruiting --> Recruiting
- || BI 764198 / Boehringer Ingelheim
New P1 trial: A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body (clinicaltrials.gov) - Nov 24, 2019
P1, N=32, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| BI 764198 / Boehringer Ingelheim
Enrollment open: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198 (clinicaltrials.gov) - Nov 13, 2019
P1, N=52, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | BI 764198 / Boehringer Ingelheim
New P1 trial: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198 (clinicaltrials.gov) - Sep 24, 2019
P1, N=52, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | BI 764198 / Boehringer Ingelheim
Trial completion, Enrollment change: A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated. (clinicaltrials.gov) - Aug 15, 2019
P1, N=72, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=48 --> 72
- | BI 764198 / Boehringer Ingelheim
Enrollment closed, Enrollment change: A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated. (clinicaltrials.gov) - Aug 4, 2019
P1, N=48, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=48 --> 72 Recruiting --> Active, not recruiting | N=72 --> 48
- ||| BI 764198 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated. (clinicaltrials.gov) - Mar 20, 2019
P1, N=72, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=72 --> 48 Not yet recruiting --> Recruiting
- ||| BI 764198 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated. (clinicaltrials.gov) - Feb 26, 2019
P1, N=72, Not yet recruiting, Sponsor: Boehringer Ingelheim